James Chalmers to Pseudomonas aeruginosa
This is a "connection" page, showing publications James Chalmers has written about Pseudomonas aeruginosa.
Connection Strength
1.602
-
Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network. Eur Respir J. 2018 01; 51(1).
Score: 0.488
-
Macrolide resistance in Pseudomonas aeruginosa: implications for practice. Eur Respir J. 2017 05; 49(5).
Score: 0.466
-
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. Lancet Respir Med. 2019 03; 7(3):213-226.
Score: 0.131
-
Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J. 2018 08; 52(2).
Score: 0.127
-
Identification of Pseudomonas aeruginosa and airway bacterial colonization by an electronic nose in bronchiectasis. Respir Med. 2018 03; 136:111-117.
Score: 0.123
-
The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. Eur Respir J. 2018 02; 51(2).
Score: 0.122
-
Anti-Pseudomonas aeruginosa IgG antibodies and chronic airway infection in bronchiectasis. Respir Med. 2017 07; 128:1-6.
Score: 0.116
-
A Randomized Controlled Trial of Atorvastatin in Patients With Bronchiectasis Infected With Pseudomonas Aeruginosa: A Proof of Concept Study. Chest. 2017 08; 152(2):368-378.
Score: 0.029